Coherus Oncology, Inc. 8-K

What Happened
Coherus Oncology, Inc. (CHRS) filed a Form 8-K on March 9, 2026 reporting that it issued a press release announcing its financial results for the quarter and fiscal year ended December 31, 2025. The full press release text is furnished as Exhibit 99.1 to the 8‑K.

Key Details

• Filing date: March 9, 2026 (Form 8-K, Item 2.02: Results of Operations and Financial Condition).
• Reporting period: quarter and fiscal year ended December 31, 2025.
• Press release furnished as Exhibit 99.1; the filing also includes an Inline XBRL cover page (Exhibit 104).
• Form 8-K signed by CEO Dennis M. Lanfear.

Why It Matters
This filing notifies investors that Coherus has released its quarterly and full‑year 2025 results — information that typically includes revenue, profit/loss, and any management commentary or guidance. The 8‑K itself does not recite the financial figures; investors should review the Exhibit 99.1 press release (and subsequent SEC filings, as applicable) to see the specific revenue, earnings, and other metrics that could affect the stock.